Lekarze w zakresie Biopsja szpiku kostnego za granicą — Strona 2

Lekarz specjalizuje się w onkologii, koncentrując się na ocenach przedoperacyjnych, wykrywaniu raka oraz udzielaniu drugiej opinii na temat żywienia i stylu życia w opiece onkologicznej. Z doświadczeniem w medycynie wewnętrznej, lekarz ukończył staż badawczy w Centrum Raka M. D. Andersona i posiada doktorat z Uniwersytetu Medycznego w Wiedniu. Lekarz pełnił funkcję głównego lekarza w Uniwersyteckim Szpitalu Medycyny Wewnętrznej I w Wiedniu i obecnie kieruje Prywatną Kliniką Josefstadt. Lekarz opublikował ponad 120 prac naukowych i jest członkiem zarządu Austriackiego Towarzystwa Hematologii i Onkologii.<\/p>

Dr. Hasan Atilla Ozkan is a hematologist at VM Medical Park Pendik Hospital in Istanbul. He is the President of the Turkish Therapeutic Apheresis Association. Dr. Ozkan specializes in stem cell transplantation and hematological oncology. He received the Young Researcher Award at the 6th Turkish Therapeutic Apheresis Congress.

• Expert in autologous and allogeneic bone marrow transplantation.
• Treats complex blood disorders including leukemia, lymphoma, and myeloma.
• Certified in clinical phytotherapy and flow cytometry application.
• Full member of the European Bone Marrow Transplantation (EBMT) group.

Lekarz jest wiodącym ekspertem w leczeniu chłoniaka nieziarniczego i specjalizuje się w leczeniu zaburzeń krwi. Z ponad 30-letnim doświadczeniem, lekarz kieruje sektorem hematologii w klinice Nordwest, koncentrując się na zaawansowanej opiece hematologicznej i badaniach.<\/p>

Dr. Mustafa Serkan Alemdar is a clinical oncologist at Medical Park Antalya Hospital Complex. He specializes in treating complex solid tumors and blood cancers. Dr. Alemdar completed his medical degree and oncology fellowship at Akdeniz University. He is an active member of the Turkish Society of Medical Oncology.

• Treats a wide range of cancers including breast, lung, and prostate.
• Expert in hematology-oncology for conditions like leukemia, myeloma, and lymphoma.
• Performs systemic therapies such as chemotherapy, immunotherapy, and targeted biological therapy.
• Works at a facility that houses specialized oncology-bone marrow units and LINAC technology.

Prof. Dr. Mehmet Sait Buğdacı is a highly experienced physician specializing in Internal Medicine and Gastroenterology. He completed his medical education and specialty training at Istanbul University Cerrahpaşa Faculty of Medicine and Şişli Etfal Training and Research Hospital. His clinical interests include gastrointestinal diseases, endoscopic procedures, and clinical research. He has contributed to medical education through numerous scientific publications and textbooks and currently sees patients at Central Hospital.

Areas of Interest • Pediatric gastrointestinal surgery • Anorectal malformations and motility disorders • Minimally invasive pediatric surgery • Pediatric colorectal and pelvic floor disorders

Lekarz jest wysoko wykwalifikowanym specjalistą w dziedzinie onkologii dziecięcej i hematoonkologii w Centrum Medycznym Hadassah, uznanym na liście najlepszych lekarzy w Izraelu według Forbes na lata 2019-2020. Z ponad dwudziestoletnim doświadczeniem w specjalizacji w pediatrii, hematoonkologii dziecięcej i haploidentycznym przeszczepie szpiku kostnego, lekarz jest wybitną postacią w tej dziedzinie.<\/p>

Lekarz jest absolwentem Uniwersytetu w Tel Awiwie i aktywnie uczestniczy w stowarzyszeniach zawodowych, w tym w Izraelskim Towarzystwie Hematologii i Onkologii Dziecięcej, Izraelskim Stowarzyszeniu Walki z Rakiem, Międzynarodowym Stowarzyszeniu Onkologii oraz Międzynarodowym Towarzystwie Onkologii Dziecięcej. Główne obszary zainteresowań obejmują siatkówczaka, medycynę precyzyjną i onkologię dziecięcą.<\/p>

Dr. Boaz Liberman, MD, is an orthopedic oncologist and sarcoma surgeon for adults and children. He directs the Orthopedic Oncology Unit and serves as Vice Head of Orthopedic Surgery at Sheba Medical Center. His focus is limb-sparing cancer surgery with functional reconstruction. He performs complex joint reconstruction, revision arthroplasty, MRgFUS, and reconstruction after bone metastases.

Education and training: MD, Tel Aviv University. Orthopedic surgery residency, Sheba Medical Center. Fellowships in Adult Reconstruction at Mount Sinai Hospital, Toronto, and in Orthopedic Oncology at Mount Sinai Hospital and Princess Margaret Cancer Centre. He is board-certified in Orthopedic Surgery and in Orthopedic Oncology Surgery. He is a Clinical Instructor at Tel Aviv University. Memberships include the Israel Medical Association, Israel Orthopedic Association, AATB, and EATB. He also serves on national advisory committees. His research covers bone and soft tissue sarcomas, serum markers, imaging-guided therapies, MRI arthrography, and the biomechanics of bone treated with MRgFUS.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Lekarz ukończył Szkołę Medyczną Hacettepe w 1985 roku i został specjalistą chorób wewnętrznych na Uniwersytecie Ege w 1990 roku. Pogłębiając swoją wiedzę, lekarz specjalizował się w hematologii i ukończył doktorat w Japońskiej Szkole Medycznej Mie w 1995 roku. Do 1997 roku lekarz awansował na stanowisko adiunkta, a następnie profesora hematologii na Uniwersytecie Ege. W 2003 roku lekarz kontynuował pracę jako profesor hematologii na Uniwersytecie Technicznym Karadeniz. Z ponad 65 artykułami naukowymi, 112 referatami na spotkaniach i 34 prezentacjami konferencyjnymi, lekarz jest uznawany za wkład w hematologię i przeszczepy szpiku kostnego.<\/p>